Revelation Biosciences, Inc. Common Stock (REVB) is a publicly traded Healthcare sector company. As of May 21, 2026, REVB trades at $1.09 with a market cap of $4.06M and a P/E ratio of -0.04. REVB moved +0.00% today. Year to date, REVB is -67.52%; over the trailing twelve months it is -96.38%. Its 52-week range spans $0.88 to $241.92. Analyst consensus is buy with an average price target of $16.00. Rallies surfaces REVB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Revelation Biosciences Secures FDA OK for Phase 2/3 Gemini Trial, Boosts Cash to $14.1M: Revelation Biosciences secured FDA agreement on a single adaptive Phase 2/3 study of its Gemini candidate for acute kidney injury and raised $6.7 million from a warrant inducement. The company ended Q1 with $14.1 million in cash (up from $10.7 million) and posted a $3.0 million net loss ($2.71/share).
| Metric | Value |
|---|---|
| Price | $1.09 |
| Market Cap | $4.06M |
| P/E Ratio | -0.04 |
| EPS | $-23.95 |
| Dividend Yield | 0.00% |
| 52-Week High | $241.92 |
| 52-Week Low | $0.88 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-8.91M |
| Gross Margin | 0.00% |
1 analysts cover REVB: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.00.